Product Highlight - QTERN
29 Nov 2019
• Superior HbA1c reduction vs DPP4i +Met or SGLT2i +Met1
• Nearly 2x patients achieved HbA1c <7%1
• Established safety profile of DPP4i with additional benefits of SGLT2i3,5-8
• Extends oral therapy with a once daily tablet4-7
References:
1. Rostenstock J, et al. Diabetes Care 2015; 38(3):376·383.
2. T. Vilsboll, et al. Dapagliflozin plus Saxagliptin shows noninferior HbA1c reductions vs insulin Glargine in patients with Type 2 Diabetes Inadequately.
3. Qtern Malaysia Prescribing Information, AstraZeneca, 2019.
4. Lokhandwala T, et al. J Med Econ. 2016: 19: 203-12.
5. Del Prato S, et al. Diabetes Obes Metab 2018; 20: 1542·1546.
6. Matthaei S, et al. Diabetes Care. 2015: 38: 2018-2024.
7. Bailey CJ, et aI. Lancet 2010; 37: 2233-33.
8. Del Prato S, et al. Diabetes Obes Metab 2015;17: 581-90.